Tullika Garg

Dr. Tullika Garg

orcid

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 May 2017 in BMC Medical Genomics
Verified
Journal Article
Open access
PDF file
MSManu Shivakumar
Manu Shivakumar
YLYounghee Lee
Younghee Lee
LBLisa Bang
Lisa Bang
TGTullika Garg
Tullika Garg
KSKyung-Ah Sohn
Kyung-Ah Sohn
DKDokyoon Kim
Dokyoon Kim
One of the fundamental challenges in cancer is to detect the regulators of gene expression changes during cancer progression. Through transcriptional silencing of critical cancer-related genes, epigenetic change such as DNA methylation plays a crucial role in cancer. In addition, miRNA, another major component of epigenome, is also a regulator at the post-transcriptional levels that modulate transcriptome changes. However, a mechanistic role of synergistic interactions between DNA methylation and miRNA as epigenetic regulators on transcriptomic changes and its association with clinical outcomes such as survival have remained largely unexplored in cancer. In this study, we propose an integrative framework to identify epigenetic interactions between methylation and miRNA associated with transcriptomic changes. To test the utility of the proposed framework, the bladder cancer data set, including DNA methylation, miRNA expression, and gene expression data, from The Cancer Genome Atlas (TCGA) was analyzed for this study. First, we found 120 genes associated with interactions between the two epigenomic components. Then, 11 significant epigenetic interactions between miRNA and methylation, which target E2F3, CCND1, UTP6, CDADC1, SLC35E3, METRNL, TPCN2, NACC2, VGLL4, and PTEN, were found to be associated with survival. To this end, exploration of TCGA bladder cancer data identified epigenetic interactions that are associated with survival as potential prognostic markers in bladder cancer. Given the importance and prevalence of these interactions of epigenetic events in bladder cancer it is timely to understand further how different epigenetic components interact and influence each other.

1 February 2018 in Journal of Urology
Verified
Journal Article
Closed access
TGTullika Garg
Tullika Garg
AYAmanda J. Young
Amanda J. Young
KKKorey A. Kost
Korey A. Kost
JDJohn F. Danella
John F. Danella
SLSharon Larson
Sharon Larson
HKH. Lester Kirchner
H. Lester Kirchner
We describe age, multiple chronic condition profiles and health system contact in patients with urological cancer. Using Geisinger Health System electronic health records we identified adult primary care patients and a subset with at least 1 urology encounter between 2001 and 2015. The Agency for Health Care Research and Quality Chronic Condition Indicator and Clinical Classifications Software tools were applied to ICD-9 codes to identify chronic conditions. Multiple chronic conditions were defined as 2 or more chronic conditions. Patients with urological cancer were identified using ICD-9 codes for prostate, bladder, kidney, testis and penile cancer. Inpatient and outpatient visits in the year prior to the most recent encounter were counted to document health system contact. We identified 357,100 primary care and 33,079 urology patients, of whom 4,023 had urological cancer. Patients with urological cancer were older than primary care patients (71 vs 46 years) and they had more median chronic conditions (7 vs 4). Kidney and bladder cancer were the most common chronic conditions (median 8 patients each). Coronary artery disease and chronic kidney disease were common in urological cancer cases compared to mental health conditions in primary care cases. Patients with urological cancer who had multiple chronic conditions had the most health system contact, including 32% with at least 1 hospitalization and 68% with more than 5 outpatient visits during 1 year. Urology patients are older and more medically complex, especially those with urological cancer than primary care patients. These data may inform care redesign to reduce the treatment burden and improve care coordination in urological cancer cases.

20 January 2018 in Bladder Cancer
Verified
Journal Article
Open access
PDF file
TGTullika Garg
Tullika Garg
JCJill Nault Connors
Jill Nault Connors
ILIlene G. Ladd
Ilene G. Ladd
TBTyler L. Bogaczyk
Tyler L. Bogaczyk
SLSharon L. Larson
Sharon L. Larson
Background: Although approximately 75% of bladder cancers are non-muscle invasive (NMIBC) at diagnosis, most research tends to focus on invasive disease (e.g., experiences related to radical cystectomy and urinary diversion). There is a lack of studies on quality of life, and especially qualitative research, in bladder cancer generally. As a result, relatively little is known about the experiences and needs of NMIBC patients. Objective: To understand patient experience, define care priorities, and identify targets for care improvement in NMIBC across the cancer continuum. Methods: Through focus groups, patients treated for NMIBC (stage <T2) were invited to share their care experiences including diagnosis, treatment, and survivorship. Transcripts were analyzed using conventional content analysis to identify themes and subthemes. Results: Twenty patients (16 male, 4 female, all white) participated in three focus groups. Five primary themes emerged: access to care, provider characteristics and communication, quality of life, goals of care/influences on decision-making, and role of social support. Patients with NMIBC desired timely access to care and honest and caring provider communication. They described urinary function and emotional quality of life changes resulting from diagnosis and treatment. Avoiding cystectomy and being alive for family were the major decision influencers. Conclusion: In this qualitative study, we identified access to care, provider characteristics and communication, quality of life, values/influences on decision-making, and social support as priority areas to improve patient experience in NMIBC. Care redesign efforts should focus on improving access, enhancing provider communication, reducing side effects, and supporting caregiver roles.

1 July 2017 in Urology Case Reports
Verified
Journal Article
Open access
AHAndrew Higgins
Andrew Higgins
TGTullika Garg
Tullika Garg
Aerococcus urinae is a rare organism isolated from urine cultures. We present a case of an 80 year-old male with bladder cancer and multimorbidity who developed A. urinae infection. A. urinae may cause simple and complicated UTIs, bacteremia, and endocarditis in older adults with multimorbidity, chronic urinary retention, or indwelling catheters. A. urinae treatment should employ penicillin, amoxicillin, and nitrofurantoin. Due to increasing antibiotic resistance, urine culture should include antibiotic susceptibility testing. Prompt and culture-specific treatment is critical to avoid clinical progression of the infection.

18 January 2021 in Journal of the American Geriatrics Society
Verified
Journal Article
Open access
PDF file
CCCarling Cheung
Carling Cheung
MMMatthew A. Meissner
Matthew A. Meissner
TGTullika Garg
Tullika Garg
This editorial comments on the article by Thillainadesan et al . in this issue.

4 November 2020 in Cancer
Verified
Journal Article
Closed access
PDF file
TGTullika Garg
Tullika Garg
CMCarmit K. McMullen
Carmit K. McMullen
MLMichael C. Leo
Michael C. Leo
MOMaureen C. O’kEeffe‐Rosetti
Maureen C. O’kEeffe‐Rosetti
SWSheila Weinmann
Sheila Weinmann
MNMatthew E. Nielsen
Matthew E. Nielsen